diagnost tool
price close busi octob
immunoassay platform lab help research
pharma determin role protein biomark
area like neurolog oncolog cardiolog
inflamm infecti diseas
initi coverag
precis medicin enabl
multipl wave growth initi buy pt
initi coverag buy rate pt view
precis medicin pure-play well posit disrupt attract life scienc
research market ultra-high sensit digit singl molecul array simoa
immunoassay instrument platform enabl research detect protein
biomark blood imposs detect convent analog
system area like neurolog oncolog cardiolog inflamm infecti
diseas longer term think investor target growth across
four phase expans life scienc research current follow possibl
entri sever addit attract market companion diagnost
assay develop point-of-car diagnost precis health well
screen billion pt use ev/sal multipl
revenu estim discount back year discount rate
size get start expect
continu make inroad life scienc research market achiev
growth next two year model exclud potenti entri major
new segment view point-of-car diagnost major new opportun
demonstr posit correl elev level protein
biomark neurolog diseas includ traumat brain injuri could
meet unmet need rapidli diagnos concuss sport event exampl
four phase growth -- earli life scienc research
penetr life scienc research market howev time think
well suit enter multipl attract high-multipl segment includ companion
diagnost point-of-car diagnost precis health well screen -- three
free call option estim combin larg custom includ
roch well lab like lh covanc
rise pharma interest work top pharma biotech
market cap technolog use phase ii trial
think well suit becom companion diagnost partner
razor-razorblad instrument model earli day simoa digit
immunoassay platform instal base system differenti
ultra-high sensit multiplex capabl expect meaning acceler
reagent annuity/box box box time
launch addit test menu oncolog cardiolog inflamm infecti
diseas offer menu assay larger free-stand analyz
assay benchtop sr-x analyz
interest role biomark never higher key area today
neurolog drive consum revenu driven panel
biomark tau neurofila light nfl platform detect elev
level protein biomark blood enabl research studi role protein
biomark area like traumat brain injuri alzheim diseas parkinson
diseas multipl sclerosi dementia cte
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
initi coverag
precis medicin enabl multipl
wave growth initi buy rate
initi coverag buy rate pt similar
ilmn-nasdaq buy believ well-posit enabl
benefit precis medicin mega-trend howev next-
gener proteom compani pre-emin genom
compani believ investor research today push
envelop multi-om take us believ dna pair
rna protein unlock new discoveri precis medicin think
build momentum go proteom player
view precis medicin pure-play well posit disrupt
attract life scienc research market ultra-high sensit digit singl
molecul array simoa immunoassay instrument platform enabl
research detect protein biomark blood imposs detect
convent analog system area like neurolog oncolog cardiolog
inflamm infecti diseas longer term think investor
target growth across phase expans life scienc research
current follow possibl entri sever addit attract market like
companion diagnost assay develop point-of-car diagnost
precis health well screen billion aggreg
compani estim pt use ev/sal multipl revenu
estim discount back year discount rate
platform sold life scienc research enabl detect
protein biomark extrem low concentr multipl sampl type
protein biomark identifi simoa mani case undetect use exist
immunoassay technolog given legaci platform lower-sensit
sensit enough detect low-abund protein marker proven
valuabl field neurolog serv qtrx key therapeut area simoa
enabl life scienc research explor role protein biomark human
health may use futur develop sensit diagnost test
compani overview histori
found april dr nichola naclerio dr david walt
scientif founder rais roughli privat fund prior
success ipo decemb provid addit
gross proce recipi grant head
health challeng program launch nation footbal leagu
gener electr spur innov test treatment traumat brain injuri
notabl privat investor includ ventur partner bain capit
ventur flagship ventur biomrieux among other
compani employ individu across sale market engin
 manufactur oper administr grew
headcount first half employ individu
headquart lexington hold corpor offic
in-hous acceler laboratori leas squar feet offic lab
manufactur space headquart leas addit
lab/manufactur space nearbi billerica
diagnost tool
initi coverag
research detect defin valid function novel protein ultra-low
level sell simoa platform assay kit primarili life scienc
research biopharma compani use technolog identifi
understand role protein biomark field neurolog oncolog
cardiolog inflamm infecti diseas beyond also provid contract
research servic custom acceler laboratori includ sampl test
custom assay develop qtrx grow custom base made
custom across end market includ top
biopharmaceut compani market capit
consum acceler lab
platform-bas razor-razorblad instrument compani also offer in-
hous lab servic instrument equip proprietari
simoa technolog key enabl ultra-high sensit simoa digit
immunoassay platform base tradit enzyme-link immunosorb assay
elisa technolog wide use method detect
protein year simoa differ convent elisa abil trap
singl molecul tini microwel trillionth millilit billion
time smaller tradit elisa well allow analysi digit readout
individu molecul possibl convent elisa technolog
abil key simoa ultra-sensit detect capabl averag
impress improv sensit current immunoassay
believ differenti competitor due superior
accuraci sensitivity/specif abil multiplex strong manag
team board investor base compani flagship analyz capabl
plex assay may abl achiev futur qtrx simoa
technolog enabl multiplex use bead label differ fluoresc
dye specif biomark analyz assay run array
microwel imag across wavelength differ label bead
result measur protein captur differ bead
abl identifi differenti differ bead subpopul
simoa analyz compani believ prerequisit develop
assay capac detect equival number protein singl sampl
diagnost tool
initi coverag
launch flagship simoa analyz januari fulli
autom floor-stand instrument process sampl per
shift analyz four biomark per test possibl expand
futur intern softwar analyz digit imag
produc instrument provid custom detail analysi
sampl includ concentr multipl biolog molecul
develop next-gen fully-autom analyz name hd-x expect launch
expect hd-x serv qtrx next-gen high-throughput instrument
enhanc softwar eas use technic featur dont expect
hd-x incorpor dna/rna id featur includ sr-x benchtop
place instrument global includ
contract research organ neurolog custom
grew instal base roughli y/i pace expect
continu next two year list analyz
estim averag sell price
discount testimoni valu instrument
fact instrument larg sold larg pharmaceut compani major
academ lab compani placement capit sale
in-vitro diagnost instrument often obtain much higher percentag
placement reagent rental agreement capit obtain front
diagnost tool
figur fully-autom easi oper
initi coverag
quanterix launch sr-x benchtop analyz decemb sr-x use
simoa technolog assay kit compact benchtop form
lower price sr-x unlik detect measur nucleic acid
dna/rna marker addit protein marker support detect capabl
biomarkers/test potenti expand time
workflow sr-x differ assay incub
wash step perform outsid instrument use convent liquid
handl method offlin sampl prep help enabl research appli
simoa detect nucleic acid process time imag well plate
hour offer approxim assay sr-x
book sr-x order instrument
instal custom site expect annual pull-through sr-x
roughli roughli half pull-through system certain
custom adopt sr-x system
activ develop addit bench top instrument
incorpor planar technolog acquir aushon biosystem
ultra-high sensit simoa make enhanc exist
instrument believ new version may capabl achiev multiplex
given expect multiplex capabl believ planar array
technolog expand capabl oncolog infecti diseas test
believ may launch instrument earli end
diagnost tool
initi coverag
ad planar array technolog acquir aushon biosystem
march aushon planar array technolog style multiplex protein
detect technolog blend protein array elisa creat mini-microarray
microtit plate formata multiplex elisa believ acquir planar
technolog complement exist simoa bead-bas technolog greater
consum assay reagent bead
provid custom ready-to-us assay well compon
requir run homebrew assay customiz assay qtrx consum
sale includ simoa disc cuvett dispos tip bead captur detect
reagent enzym reagent enzym substrat
focus drive adopt sr-x instrument base
increas consum util per analyz basi introduct
new assay applic new enhancements/upgrad instrument
track ahead consum util goal
per instrument per year though certain custom track much higher see
figur expect averag util rate sr-x bench top system
half deliv consum revenu
vs y/i
diagnost tool
figur certain custom far-exceed qtrx annual goal pull through/box
initi coverag
in-hous acceler lab provid cro servic custom
support wide varieti project includ sampl test homebrew custom
assay develop complet project custom
date custom subsequ purchas simoa instrument
use acceler servic gain access acceler lab
acquisit aushon biosystem ran clia lab billerica
integr acquir clia lab acceler lab system oper
analyz believ clia-lab accredit help acceler entri
pharmaceut servic deliv servic collabor
revenu vs y/i within categori acceler
clia lab servic revenu came vs
y/i projects/servic offer acceler lab includ
sampl test simoa kit run larg studi custom
thousand specimen small studi custom sampl
sampl protocol tailor precis custom need even larg
studi run quickli experienc use variou sampl type
biomark may present low level
homebrew assay develop use proprietari reagent combin
homebrew assay develop kit rapidli develop prototyp assay
higher sensit convent elisa acceler lab also use
screen reagent identifi optim assay format expand prototyp effort
assay optim valid deliv highest level perform
custom develop acceler lab use gener qualifi bulk
reagent custom assay kit provid custom access valid kit assay
yet commerci avail simoa platform
diagnost tool
initi coverag
proteom diagnost
global tam long term financi target
peg total global tam includ life scienc research
pharma servic diagnost precis health screen market
estim life scienc research pharma services/biotech opportun
total opportun diagnost precis health screen
within diagnost precis health screen believ simoa
technolog may prove disrupt within point care immunoassay molecular
traumat brain injuri alzheim pancreat cancer
figur earli penetr initi life scienc research market today target much larger time
time see path achiev gross margin scale
achiev like razor-razorblad compani quanterix
expect higher gross margin consum servic
partial off-set lower gross margin instrument
establish lt revenu target comment expect
achiev profit employ peopl
commerci organ manufactur oper
diagnost tool
initi coverag
proteom research includ studi protein immun respons
function physic mental health time protein complex molecul
requir structur function regul bodi tissu
organ function unit carri specif task everi cell
accord human bodi contain approxim gene
produc multipl protein estim gene
produc differ protein known secret
blood argument protein detect research nucleic acid
genom research provid valuabl inform role gene health
diseas protein preval thu relev precis
understand nuanc continuum health diseas protein
measur goe beyond genet predisposit reflect impact rang
influenc health includ environment factor lifestyl provid deeper
relev insight happen person bodi real time
seek disrupt life scienc research market ultra-high
sensit immunoassay platform simoa histor proteom research market
domin compani use tradit enzyme-link immunosorb
assay elisa employ antibodi color chang identifi substanc
addit elisa technolog avail protein analysi today
reson raman-enhanc signal detect immune-pcr biobarcod assay
thermo fisher player immunoassay market along
smaller competitor singulex millipor sigma
mesoscal diagnost target research clinician util protein
detect research and/or clinic tool qtrx differenti simoa platform
look solv major problem exist tradit immunoassay techniqu
often tradit platform detect protein theyv reach level
reflect advanc diseas injuri believ simoa sensit offer
way detect protein earli diseas cascad thu enabl earli intervent
advanc stage injuri diseas
proteom research fall within overarch trend precis medicin
seek tailor medic treatment individu characterist patient
firm believ era precis medicin earli day character
rapid advanc instrument assay biomark explor
research global believ multi-om approach precis
medicin includ use proteom genom metabolom
biomark uncov health advanc expect protein biomark detect
play major role precis medicin thu consid well-posit
capit excit megatrend
addit protein biomark research qtrx simoa platform identifi nucleic
acid genom biomark nucleic acid detect current avail qtrx
sr-x benchtop reader expect includ upgrad compani
next-gener hd-x instrument believ simoa potenti
provid sensit polymeras chain reaction pcr
commonli use technolog nucleic acid detect without distort bia
issu associ amplif use pcr competitor within
refer lab labcorp compani develop gene-
diagnost tool
initi coverag
peg total life scienc research market address simoa includ
proteom genom research billion per year potenti
reach billion per year time
companion diagnost test biomark test specif link drug
often use predict patient respond drug drug
develop explor simoa tool stratifi patient categori enabl
select patient drug expect effect safe
research hope simoa prove use stratifi patient clinic
trial treatment thu enabl develop companion diagnost
base protein biomark regularli monitor whether approv drug
desir biolog effect- allow doctor quickli effici adjust
cours treatment appropri believ simoa prove use
develop companion diagnost evidenc grow pipelin
pharma top biopharma market cap similar platform
compani cover believ may earn credit stock price major
new public data releas certainli upon sign either
figur companion diagnost deal futur major pharmaceut
compani size companion diagnost opportun billion
in-vitro diagnost ivd instrument platform point-of-car diagnost
believ qtrx third major wave growth mark entranc
in-vitro diagnost ivd market appear ampl runway
life scienc market believ clinic diagnost present compel futur
opportun specif within field in-vitro diagnost point-of-car
diagnost believ ultra-high sensit simoa may help improv
current diagnost test integr protein detect futur may help
advanc next-gener non-invas diagnost test replac
invas gold standard within field neurolog believ may abl
develop point care test traumat brain injuri use sidelin
sport event battlefield enter collabor
agreement biomrieux use simoa develop applic diagnost
ivd market termin agreement earli septemb due
differ diseas focu biomrieux primarili infecti diseas focus
neurolog oncolog focus view termin posit consid
simoa compel differenti platform may draw interest form
partnership number larg diagnost compani includ roch
novarti abbot even poc pure-play
point care poc test design use near site patient
locat perform outsid clinic lab player poc market includ
abbott aler roch orasur chembio
size core lab immunoassay market billion point-
of-car diagnost market anoth aggreg diagnost tam
upon receipt regulatori approv fda clia-waiv etc
liquid biopsi simpl non-invas altern invas surgic tissu
biopsi enabl doctor discov rang inform tumor
simpl blood draw trace diseas biomark protein dna
blood give clue health risk treatment decis overal patient
diagnost tool
initi coverag
well believ simoa abil detect quantifi normal
physiolog level low abund protein enabl technolog use
monitor protein biomark level seemingli healthi asymptomat peopl
potenti signal provid earlier detect onset diseas
believ potenti number neurolog cardiovascular oncolog
protein biomark associ diseas measur simpl
blood draw regular on-going basi part patient routin health screen
result compar period baselin measur
predict detect earli onset diseas prior appear symptom
believ qtrx simoa platform potenti play import role
liquid biopsi futur integr protein biomark detect view
liquid biopsi market compel opportun believ
current stock factor opportun precis health screen
size precis health screen market approxim billion base
potenti launch new applic follow area
pancreat cancer screen monitor
therapeut area neurolog focu
neurolog primari therapeut area key differenti vs
life scienc instrument compani ultra-high sensit simoa enabl
research detect neurolog biomark blood ultra-low level
previous detect cerebrospin fluid csf liquid around
person brain spinal cord csf sampl nearli plenti blood
obtain spinal tap lumbar punctur doctor place long
needl two vertebra bone surround spinal cord spine
take minut requir local anesthet often requir rest
punctur ventricular drain lower sensit tradit protein detect
method challeng due blood-brain barrier form
endotheli cell line cerebr microvasculatur thu restrict movement
protein substanc blood circul
featur neurolog focus scientif public span
differ biomark shown applic across rang neurolog
dementia parkinson diseas multipl sclerosi traumat brain injuri cte
degen brain diseas found athlet militari veteran other
histori repetit brain trauma cte protein call tau form clump slowli
spread throughout brain kill brain cell custom explor simoa
help develop cut edg accur diagnost tool predict health
screen ultim effect treatment within field neurolog
diagnost tool
initi coverag
carv nich research recipi
grant head health challeng program launch
nation footbal leagu spur innov test
treatment select winner grant
entri across countri panel healthcar expert field brain
research imag technolog also particip nfl health
safeti updat interact head health showcas super bowl
simoa demonstr sensit detect elev level protein
biomark follow traumat brain injuri may help doctor assess brain
health critic moment follow incid estim tbi lead
emerg room visit per year individu receiv ct scan fail
diagnos mild tbi simoa use number neurolog biomark
includ neurofila light nf-l tau evalu brain health
pois enabl next wave research cte alzheim three
neurolog condit present major opportun life scienc research
diagnost compani pharma opinion
tau- tau microtubule-stabil protein primarili locat central nervou
system neuron research explor tau biomark neuron damag
neurodegen diseas earli research discov elev level
tau may damag brain cell essenti learn memori thu tau view
promis biomark alzheim dementia cte traumat brain injuri
parkinson neurodegen diseas tau elev observ
cerebrospin fluid csf patient neurodegen diseas head
injuri suggest extracellular releas neuron damag role
biomark specif brain injuri genet form frontotempor dementia
ftd mutat tau implic abnorm tau initi neurodegener
ftd deposit tau present tempor frontal lobe brain
critic behavior execut function offer proprietari tau
assay stand-alone test part neurolog panel
neurofila light nfl neurofila light nfl cytoskelet intermedi
filament protein express neuron neurofila major compon
neuron cytoskeleton believ function primarili provid
structur support axon brain serv primari transmiss line
central nervou system nfl suggest marker
neurodegener number neurodegen diseas includ amyotroph
later sclerosi al traumat brain injuri alzheim dementia other
simoa assay digit immunoassay quantit determin
nfl serum plasma csf custom order nfl stand-alone assay
part neurolog panel
diagnost tool
figur offer stand-alone neurolog assay target assay
initi coverag
oncolog serv key therapeut area major compon
larg total address market estim total address market
simoa oncolog may reach billion time includ research
diagnost precis health screen indic research util simoa
detect abnorm level oncolog biomark earli stage diseas
develop patient becom symptomat ultra-high sensit simoa
ideal may provid earlier detect better monitor treatment non-
invas way date scientif public cancer
biomark use simoa technolog
look capit emerg cancer immunotherapi
companion diagnost evalu patient immun respons drug base
presenc certain protein biomark given immunotherapi drug often
evok immun respons vari person protocol companion diagnost add
valu stratifi patient predict respons reveal mechan action
predict side effect develop set ultrasensit immun
modul assay cytokin chemokin use directli monitor
patient immun respons ultra-sensit assay major immuno-
post-surgeri treatment develop test market
fold sensit benchmark commerci assay
offer stand-alone assay use detect presenc
program cell death protein cell surfac receptor play
role activ immun system target cancer
treatment bound anoth protein call help keep cell
kill cell thu enhanc anti-tumor immun improv cancer
immunotherapi certain instanc inhibitor approv clinic
use europ us pembrolizumab keytruda nivolumab
opdivo drug shown help treat sever type
cancer includ non-smal cell lung cancer melanoma skin kidney cancer
bladder cancer head neck cancer hodgkin lymphoma
offer stand-alone assay use detect presenc
program cell death receptor ligand protein express
may inhibit bodi abil fight infect diseas includ cancer
bind receptor t-cell call inactiv t-cell abil fight
cancer three inhibitorsatezolizumab tecentriq avelumab bavencio
durvalumab imfinzi approv cancer immunotherapi sever advanc
diagnost tool
initi coverag
cancer includ bladder cancer non-smal cell lung cancer merkel cell skin
cancer merkel cell carcinoma drug also studi use
type cancer
offer simoa total assay test two major form
complex uncomplex prostate-specif antigen blood
protein produc normal well malign cell prostat gland
blood level often elev men prostat cancer test
origin approv fda monitor progress prostat cancer
men alreadi diagnos diseas typic
undetect convent assay method follow surgeri
figur believ multiplex capabl prove valuabl field oncolog
cardiolog inflamm infecti diseas
neurolog oncolog qtrx largest two therapeut area simoa
shown promis field cardiolog inflammatori diseas infecti
diseas heart diseas relat cardiovascular disord lead caus
death death accord cdc seek correl
cardiac biomark earli predict advers event outsid cardiolog
simoa assay shown util measur inflammatori anti-inflammatori
molecul serum plasma proven correl rang
inflammatori diseas includ crohn diseas asthma rheumatoid arthriti
neuro-inflamm see potenti sign partnership compani
develop anti-inflammatori drug quantifi effect drug
inflammatori molecul monitor therapeut efficaci infecti diseas
look compet sell assay detect infecti diseas biomark
onset immun respons viru contagi
believ sensit simoa may enabl detect infecti diseas
specif antigen low level detect tradit immunoassay
believ high sensit simoa technolog rival pcr-base
nucleic acid detect relat identifi infecti diseas biomark
diagnost tool
initi coverag
assess heart health troponin-t troponin-i protein releas blood
heart muscl damag damag heart
greater amount troponin blood clinic studi
demonstr cardiac troponin-i ctni slowli releas blood within
hour myocardi infarct mi ischem damag ctni measur
use identifi cardiac injuri differ sourc includ surgeri trauma
intens exercis
figur quanterix look serv unmet need cardiolog expand menu cardiac biomark
commerci organ go-to-market
four phase growth life scienc companion diagnost in-vitro
diagnost ivd /point-of-car diagnost precis health screen
target four stage growth driven life scienc research market
companion diagnost point-of-car diagnost routin precis health
well screen
commerci strategi present target life scienc research market
includ research organ commerci academ government
interest proteom genom look drive instrument adopt within
life scienc research organ pharma compani driven direct
sale rep third-parti distributor instal base expand target
increas consum util test menu expans cost improv
develop new applic also drive revenu
acceler lab offer number contract research project servic
complet project custom acceler lab
custom subsequ purchas instrument
aspect qtrx commerci strategi
scale commerci organ direct sale rep third-parti distributor
expand commerci capabl relat lab infrastructur
headcount includ new equip technolog system qualiti personnel
end employ member commerci organ
ad includ direct sale repres technic
field applic scientist sell instrument assay research use
direct field sale support organ north america
europ combin direct sale rep third-parti distributor
australia china india japan lebanon singapor south korea taiwan
diagnost tool
initi coverag
drive adopt stem scientif valid
look drive adopt provid evid scientif valid
peer-review public quanterix simoa technolog cite
articl peer-review public includ jama neurolog natur cover
biomark becom vital tool cut edg life scienc research
establish relationship key opinion leader grow base
custom includ world lead academ
govern research institut well largest pharmaceut
leverag simoa ecosystem expand custom base
penetr exist custom base
drive consum util instal base launch custom
outreach program call catalyz custom engag cce cce
sale rep activ engag custom optim workflow better
understand instrument product capabl
util flexibl simoa platform expand reach nucleic acid detect
leverag simoa platform applic outsid proteom
includ nucleic acid detect believ simoa technolog
detect nucleic acid sensit pcr-base techniqu without
issu associ pcr amplif
leverag data gener simoa drive adopt
plan use data gener simoa improv creat addit
assay goal enabl precis research today contribut
precis health futur
grow new market strateg collabor
partnership place lead diagnost compani plan
continu evalu strateg collabor could help access new
market may look sign companion diagnost deal top pharma
compani seek sign partnership top point-of-car diagnost compani
new instrument assay launch
commerci launch simoa analyz januari sr-
 benchtop reader capabl protein nucleic acid detect
develop next-gen fully-autom free-stand instrument planar
technology-bas benchtop instrument capabl expect
advanc qtrx capabl oncolog
offer assay sr-x compani acquir
assay multiplex acquisit aushon biosystem
process reconcil planar technology-bas assay
simoa bead technolog plan launch assay simoa-t planar
diagnost tool
initi coverag
see nine catalyst
expect compani continu invest global commerci organ
includ direct sale forc expans /e new distribut
capabl asia-pacif region sell instrument consum
servic direct salesforc support organ north america
europ distributor sale agent select market
call approxim peopl employ sale sale support
market includ direct sale rep technic field applic
scientist expect qtrx expand commerci organ drive instrument
adopt util gain frequenc custom contact increas
new instrument launch hd-x planar technolog benchtop reader
develop hd-x next-gener free-stand fulli autom
analyz expect launch formal hd-x expect offer
number softwar hardwar improv along expand multiplex
capabl await inform regard spec new box
time launch
gain access aushon biosystem planar array technolog
acquir aushon march consid planar technolog
multiplex protein detect technolog complimentari exist simoa bead
technolog believ lead effici point-of-car solut upon qtrx
push diagnost develop simoa-t planar technology-
base benchtop instrument expect achiev plex given
expect multiplex capabl believ planar array technolog
expand capabl oncolog infecti diseas test
boast menu assay focus neurolog simoa bead
technolog target launch assay year-end
acquisit aushon biosystem gain access addit assay
base acquir planar array technolog portion aushon
assay overlap work reconcil test
use next-gen simoa-t planar benchtop instrument target
launch oncolog panel planar instrument
focus expand assay menu roll new applic simoa
platform driven input kol homebrew acceler lab project new
public custom feedback
call three major prioriti menu expans
expand planar technolog multiplex capabl
develop oncolog test pipelin reconcil overlap
diagnost tool
initi coverag
pois four stage growth
believ pois four stage growth driven life scienc
research companion diagnost lab develop test in-vitro poc
diagnost consum health well believ investor present
valu base stage one basic zero valu phase two three
four similar platform compani cover expect qtrx stock reflect
stage two four provid evid success area
public data use ntra-nasdaq buy
exampl ntra stock inflect meaning compani proven
technolog applic area organ transplant reject oncolog outsid
expect sign partnership biopharma companion diagnost
larg dx compani point-of-car poc solut believ
attract candid sign poc partnership larg diagnost compani
termin licens agreement biomrieux posit
termin qtrx leadership neurolog didnt align biomrieux focu
infecti diseas believ larg market lead diagnost compani
roch abbot thermo along poc stand-alone may
interest explor util simoa ivd/poc set
biomark id drug develop key focu fda
well-posit benefit food drug administr evolv
stanc companion diagnost fda recent year roll initi
encourag biopharma compani identifi incorpor biomark
clinic trial design fda april advanc polici make co-develop
drug diagnost cancer trial effici particip
clinic trial date trial pipelin accord
nih budget bill includ y/i increas spend
pois benefit senat approv budget bill
increas nih spend total bill includ
number nih initi increas fund includ
brain research advanc innov neurotechnolog brain
us research program precis medicin initi total
biomed advanc research develop author barda
clinic translat scienc award total
nation action combat antibiotic-resist bacteria carb
diagnost tool
initi coverag
benefit scarciti valu
within coverag univers identifi number attract market
segment compani involv benefit scarciti valu
market segment anim health point-of-car diagnost
character above-industri growth rate small number particip
segment becom consolid scarciti valu remain player
increas becom reflect rise valuat consid quanterix
beneficiari scarciti valu given high sensit digit immunoassay
technolog would surpris see larg diagnost pharma compani
make bid time quanterix simoa digit immunoassay tout fold
improv sensit current immunoassay techniqu
believ current valu protein detect capabl
receiv littl credit relat potenti nucleic acid detect qtrx sr-
 abil measur nucleic acid dna/rna marker support detect
capabl biomarkers/test anticip expans time
believ simoa technolog potenti provid
sensit pcr-base assay detect nucleic acid without issu
associ amplif
recent oper result model
oper result deliv revenu y/i
beat consensu product revenu came y/i
service/oth acceler lab collabor revenu came
y/i improv bp y/i bp q/q driven increas
consum util stand per analyz per year opex
total y/i driven primarili ytd increas headcount
total employe look add commerci organ
key area busi balanc
provid quarterli annual revenu guidanc time
indic earn call expect similar rang
deliv see room gm improv scale
consum servic revenu reduc product input cost improv
manufactur effici burn cash finish
quarter cash balanc sheet hold debt
recent termin biomrieux agreement biomrieux announc
novemb strateg agreement gave biomrieux world-wide exclus
right quanterix simoa technolog clinic laboratori industri
applic agreement deliv new instrument
consum base simoa technolog biomrieux develop
special test high sensit multiplex requir
particular focu infecti diseas two compani sign updat
agreement allow licens simoa technolog
go market directli poc devic lab develop test ldt
amend agreement biomrieux retain right develop technolog
focus strateg prioriti septemb announc
termin licens agreement biomrieux thu reinstat
right privileg associ simoa technolog key reason
diagnost tool
initi coverag
termin differ diseas focu biomrieux infecti
diseas neurolog oncolog
model model quarterli revenu estim
detail revenu breakdown driven estim sr-x instrument
placement pull per system growth rate assum acceler lab
servic segment flow quarterli revenu estim
model lever includ cog spend sg spend tax rate
model revenu y/i
y/i y/i y/i y/i vs
consensu
figur quanterix penetr global immunoassay nucleic acid detect technolog instrument market
sell immunoassay platform assay reagent includ
magpix flexmap multiplex platform magpix
platform simplest afford compact platform
perform differ test singl reaction volum read plate
minut system instal base accord
enabl research multiplex analyt singl micropl
well minut flexmap system largest advanc
platform enabl multiplex gene protein singl sampl
flexmap run plate minut plate
diagnost tool
minut flexmap platform base flow
cytometri technolog magpix base fluoresc imag
figur luminex offer three immunoassay platform vari throughput multiplex capabl
initi coverag
diagnost tool
initi coverag
commerci immunoassay platform elisa
immunoassay compet hold
distribut suppli agreement span immunoassay
develop commerci biolog content use
test platform allow distribut multiplex
instrument includ flexmap magpix platform
major market world-wide also offer proteinsimpl ella platform
autom system allow research run singl multi-analyt elisa
hands-fre hour autom microfluid cartridg
figur bio-techn sell ella immunoassay platform subsidiari proteinsimpl
singulex millipor sigma singulex like luminex licens technolog
partner singulex develop assay use magpix
flexmap platform singulex also commerci smc singl molecul
count erenna smcxpro immunoassay system smc erenna offer
option featur assay smcxpro featur assay
figur singulex singl molecul count smc system market ultrasensit platform compet simoa smc
diagnost tool
initi coverag
gyro protein technolog gyro sweden-bas privat compani
commerci immunoassay instrument kit compani offer gyrolab
xpand high-throughput platform gyrolab xplore single-disc platform
gyrolab xpand deliv data point hour run multipl
combin method cd singl run gyrolab xplore deliv
time result low-throughput format compact benchtop instrument
figur gyro xpand analyz left lower-throughput gyro xplore analyz right
mesoscal diagnost mesoscal commerci sector quickplex
immunoassay platform sector mesoscal flagship analyz
autom platform capabl process multiplex
plate quickplex lower throughput platform measur one-fourth
size mesoscal sector platform
figur mesoscal diagnost sector left quickplex right
diagnost tool
initi coverag
nanostr nanostr commerci three instrument platform use identifi
analyz dna rna protein ncounter sprint profil benchtop
system gear toward individu research lab ncounter max analysi system
gear toward core lab high throughput user ncounter flex target
translat research laboratori clinic applic ncounter platform
allow multiplex analysi rna dna protein target
figur nanostr offer three differ immunoassay platform target custom vari size
roch diagnost june roch launch coba immunochemistri
modul newest member coba modular analyz seri coba
offer immunoassay run tests/hour test run
serum plasma urin sampl type four modul
configur seri
figur coba modul newest member coba modular analyz seri
diagnost tool
initi coverag
siemen siemen offer fulli autom immunoassay platform disease-
focus menu test siemen immunoassay platform portfolio includ
free-stand advia centaur xpt xp system immulit xpi system
siemen also offer benchtop analyz includ advia centaur cp
figur advia centaur xpt left advia centaur cp middl immulit cpi system right
small-cap compani low trade liquid thu may difficult
investor sell share quickli favor price rel competitor
public market found lack establish oper histori
may make difficult effect compet larger competitor
hand smaller compani act much nimbl larger compani
competit life scienc research diagnost
compet directli compani servic life scienc
research diagnost market includ luminex corpor
mesoscal diagnost singulex gyro corpor
upon expans health screen market siemen abbott roch ortho
clinic diagnost thermo fisher scientif face competitor
hold greater brand recognit greater financi human resourc broader
product line larger sale forc distributor network larger ip portfolio
establish custom base larger scale manufactur capabl
abil achiev profit time take get
accumul deficit expect loss
continu least next month profit reli
continu top-lin growth success instrument assay launch
expans commerci organ market penetr util uptak
delay instrument test launch regulatori reimburs decis
health custom purchas environ may extend goal
profit face challeng competitor face life
evolv industri standard intellectu properti disput price competit
diagnost tool
initi coverag
aggress market practic need invest infrastructur
advanc increas demand instrument test failur
accur forecast demand would neg impact busi
abil attain profit
commerci risk market accept
market accept depend compani abil improv exist product
introduc new product success prove offer novel
attract altern compet technolog face risk relat
custom acquisit technolog valid sale cycl instrument/test accuraci
reliabl prove econom benefit adopt technolog success
depend compani abil cater divers custom base
includ academ government research institut well
biopharmaceut contract research compani face risk relat
talent acquisit expans direct salesforc abil identifi
secur desir third-parti sale distribut partner custom demand
depend level research develop spend academ
government research institut biopharma compani
continu access capit balanc sheet
small public compani may less access capit make
harder bridg gap cash flow fuel growth opportun undertak larg
capit expenditur hold cash balanc sheet
burn cash capit expenditur requir includ sale
market expans exist product improv new product
develop launch regulatori clearanc facil headcount expans
oper financi inform system cost unabl
secur addit fund need may delay reduc scope
elimin one program sale market initi
strateg collabor licens arrang
look establish strateg collabor licens agreement
third parti develop product base simoa technolog certain vitro
diagnost ivd purpos counterparti partner priorit
collabor abil gener revenu agreement may
limit given exclus natur certain collabor may
abl collabor other area exclus licens effect
relianc singl contract manufactur
reli singl contract manufactur stratec biomed ag locat
germani manufactur suppli simoa instrument reli
singl contract manufactur paramit corpor locat ca manufactur
suppli sr-x instrument manufactur disrupt priorit project
ahead delay suppli would neg affect oper result
chang manufactur would result addit cost delay
manag execut human capital- attract retain talent
success includ research develop program
commerci execut larg depend continu abil identifi hire
develop motiv retain highli skill personnel area organ
given complex technic natur life scienc research market
failur attract recruit retain motiv qualifi personnel may pose risk
diagnost tool
initi coverag
valuat compar analysi
trade ev/sal multipl revenu estim
y/i slightli comp group averag given qtrx technolog
highli differenti tradit immunoassay platform compani believ
compani benefit scarciti valu thu command premium multipl
pt use multipl revenu estim
discount back year discount rate share outstand
compani report canaccord genuiti factset estim
select public highlight util
qtrx simoa technolog
perform evalu multiplex assay simultan detect four
david okonkwo geoffrey manley journal neurotrauma
traumat brain injuri result heterogen patholog affect multipl cell
tissu type brain like assess complex
requir simultan measur multipl molecular biomark singl
sampl biolog fluid public research measur glial fibrillari
chain nf-l total tau plasma sampl obtain subject enrol
transform research clinic knowledg traumat brain injuri pilot
track-tbi pilot studi use quanterix simoa assay research also
measur nf-l use simoa singleplex assay
research comput correl differ biomark
calcul discrimin valu biomark distinguish
subject abnorm versu normal head result show strong
correl nf-l valu deriv multiplex singleplex assay
correl coeffici among biomark valu deriv
multiplex assay strongest correl axon neuron
marker nf-l weakest correl
glial marker axon marker tau auc
diagnost tool
initi coverag
distinguish subject with/without abnorm head ct multiplex
nf-l total tau confid interv ci
respect research
conclud multiplex assay provid simultan quantif
nf-l tau may clinic use diagnosi well
identifi differ type cellular injuri
higher exosom phosphoryl tau total tau among veteran combat-
harvey levin traci nolen elisabeth wild ramon diaz-arrastia jessica gill cenc
multisit observ studi investig higher exosom phosphoryl tau
total tau among veteran combat-rel repetit chronic mild traumat brain injuri
object studi measur plasma exosom level tau
phosphoryl tau p-tau amyloid beta veteran histor mild
traumat brain injuri mtbi chronic neuropsycholog symptom tau p-tau
measur simoa plasma exosom
veteran enrol chronic effect neurotrauma consortium multicent
observ studi protein biomark compar among group
without mtbi loss conscious loc post-traumat amnesia pta
also without repetit mtbi rtbi compar
tbi-neg mtbi
result show differ measur plasma exosom protein level
among mtbi loc pta mtbi alter conscious tbi-neg
exosom tau exosom p-tau elev rtbi compar
fewer mtbi tbi-neg elev exosom tau p-tau significantli
correl post-traumat post-concuss symptom exosom tau also
relat specif cognit affect somat post-concuss symptom
research conclud repetit traumat brain injuri rtbi associ
elev exosom p-tau exosom tau suggest blood-bas
exosom may provid peripher sourc inform central deriv
biomark remot mtbi rtbi may contribut chronic
digit enzyme-link immunosorb assay ultrasensit measur
amyloid- peptid human plasma util studi alzheim
digit enzyme-link immunosorb assay ultrasensit measur amyloid-
peptid human plasma util studi alzheim diseas therapeut
amyloid- peptid associ plaqu format brain
patient alzheim diseas ad pharmacodynam studi ad therapeut
lower concentr peripher blood requir highli sensit
assay measur assay sensit enough allow accur
precis quantif low concentr plasma clinic trial
diagnost tool
initi coverag
digit elisa technolog provid sensit precis measur plasma
clinic sampl treat inhibitor
agent result public indic simoa may potenti util
clinic applic quantif plasma specif
pharmacodynam studi high sensit precis requir
biomark alzheim diseas current statu prospect futur
blennow zetterberg sahlgrenska academi univers gothenburg mlndal
sweden biomark alzheim diseas current statu prospect
tau reflect key element ad pathophysiolog number clinic
public give updat cerebrospin fluid csf biomark
alzheim diseas ad focu diagnost applic accumul data
clinic research suggest core alzheim diseas ad cerebrospin
tau phosphoryl tau
studi show biomark contribut diagnost relev
inform specif earli diseas stage technic develop
includ simoa autom improv sensit made possibl
measur biomark high precis stabil public highlight
use simoa identifi tau neurofila light
serum neurofila light nf-l biomark neuron damag multipl
schluep granziera du pasquier mller vehoff serum
neurofila light biomark neuron damag multipl sclerosi ann neurol
neurofila light chain nfl uniqu neuron cell shed
cerebrospin fluid csf detect low concentr peripher
blood variou diseas caus neuron damag result elev csf
concentr public level measur simoa healthi
control two independ ms cohort cross-sect pair serum
csf sampl longitudin repeat serum sampl
research assess relat concurr clinic imag treatment
paramet futur clinic outcom result show level
higher multipl sclerosi cohort healthi cohort research thu
found strong associ csf nfl
result support valu sensit clinic meaning blood
biomark monitor tissu damag effect therapi ms
diagnost tool
initi coverag
optim qualif singl molecul array digit immunoassay
plasma cancer patient
vinita gupta navdeep kalia mahesh yadav ami noy jeremi robert hendrick
cytokine/chemokin level reflect pharmacodynam checkpoint
inhibitor public explor role singl molecul array
simoa quantif low abund protein potenti cancer
immunotherapi mechan action studi
simoa reagent standard curv test condit optim
improv precis linear dilut plasma cancer patient assay
achiev lower limit quantif pg/ml sampl record
lower limit quantif precis cv accuraci within
research conclud simoa enabl quantif sub-pg/ml
level cancer patient superior competitor simple-plex
subsidiari aushon recent acquir overal perform studi
qualifi user-modifi immunoassay measur pharmacodynam
chang plasma cancer immunotherapi
detect interferon alpha protein reveal differenti level cellular sourc
 crow darragh duffi journal experiment medicin apr
ifna protein famili cell signal molecul play crucial role
immun system anti-vir defens inappropri activ interferon signal
caus immun system attack healthi tissu bodi lead
varieti autoimmun diseas elev interferon signal link complex
autoimmun disord lupu dermatomyos diabet mellitu
diagnos diseas understand role interferon alpha protein
patholog hamper inabl clinician directli measur
level protein patient sampl larg interferon
alpha protein present tini amount use simoa research
abl detect interferon alpha attomolar concentr equival
quadrillionth gram per millilit sampl time sensit
exist method detect protein ifna level elev
autoimmun sampl serum plasma csf sampl sle patient higher
interferon alpha level correl increas sever diseas
diagnost tool
initi coverag
diagnost tool
figur board director
initi coverag
diagnost tool
initi coverag
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
diagnost tool
initi coverag
diagnost tool
initi coverag
diagnost tool
initi coverag
